Using preoperative chest CT scans, researchers identified novel preoperative biomarkers for lung cancer recurrence ...

received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumor resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC ...

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of ...

A father from Seattle, Washington was shocked and overwhelmed after strangers came together to raise more than $150k for him to go through life-saving cancer treatment.

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...

Despite new paradigm-shifting treatments, lung cancer remains a deadly ... as the percentage of patients whose cancer cells die by more than 90% in the resected specimen, however the definition ...

Findings were similar for lung cancer-specific survival ... randomized trial showed that sublobar resection performed as well as lobectomy for NSCLC tumors ≤2 cm. Around the same time, the ...